EBT 104
Alternative Names: EBT-104Latest Information Update: 03 Jun 2025
At a glance
- Originator University of California at Berkeley
- Developer Excision BioTherapeutics
- Class Antivirals; Gene therapies; RNA
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Dendritic keratitis
- No development reported Herpes simplex virus infections
Most Recent Events
- 13 May 2025 Pharmacodynamics data from a preclinical study in Dendritic keratitis released by Excision BioTherapeutics
- 28 Sep 2024 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections in USA (Parenteral)
- 13 May 2024 Pharmacodynamics data from a preclinical studies in Herpes simplex virus released by Excision BioTherapeutics